Long-Term Treatment With Interleukin-6 Receptor Inhibitor Tocilizumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Neurology Open Access 2026 Open access

Read full text
Authors: Francesco Capecchi, Madalina Graure, Sinan Yasaroglu, Salome Schubert, Nathalie Nierobisch, Veronika Kana, Michael Weller, Patrick Roth, Marina Herwerth
DOI: 10.1212/wn9.0000000000000049
Cited by: 2
References: 31

Abstract

Data about efficacy and safety of disease-modifying therapeutic options in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) are scarce. Interleukin-6 signaling has been suggested to be involved in the pathogenesis of MOGAD. The aim of this study was to evaluate the effectiveness and safety of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in MOGAD.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Systemic Lupus Erythematosus Research Neurogenesis and neuroplasticity mechanisms

Publication details

Journal / source
Neurology Open Access
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
2
Issue
1
Publication date
9 February 2026
Language
EN